In CKD trials, the eGFR slope has emerged as a surrogate endpoint for earlier assessment of treatment effects. However, the influence of key design parameters-slope difference, trial duration, measurement frequency, and dropout patterns-on the required sample size remains unclear. We aimed to derive a sample size formula that incorporated these factors and develop a practical tool for efficient calculation across diverse trial scenarios.